Press Releases

Date	Title	Company
03-Jul-2023	Amyotrophic Lateral Sclerosis is expected to accumulate a market value of US$ 1332.22 Million by registering a CAGR of 6% 2023 to 2033	MARKITWIRED
03-Jul-2023	Drug-Induced Dyskinesia Market is expected to grow at a steady 4.25% CAGR, reaching a value of US$ 620.2 Million by 2033	MARKITWIRED
03-Jul-2023	Non-Small Cell Lung Cancer is expected to accumulate a market value of US$ 20 Billion by registering a CAGR of 7.2% 2023 to 2033	MARKITWIRED
03-Jul-2023	Swine Vaccine Market is projected to grow at a CAGR of 5.8% from 2022 to 2032	MARKITWIRED
02-Jul-2023	IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. and Encourages Investors to Contact the Firm	Businesswire
01-Jul-2023	Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA™ (adalimumab-bwwd) in Multiple Presentations Consistent with Originator	Businesswire
01-Jul-2023	Tevas dritte Zwischenanalyse der PEARL-Real-World-Studie zu AJOVY® (Fremanezumab) zeigt anhaltende langfristige Wirksamkeit bei der Verringerung von Häufigkeit, Dauer und Schwere der Anfälle bei Patienten mit chronischer und episodischer Migräne	Businesswire
01-Jul-2023	FATE THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fate Therapeutics, Inc. - FATE	Businesswire
01-Jul-2023	Resumen: Tercer análisis intermedio de Teva del estudio PEARL de la vida real sobre AJOVY® (fremanezumab) revela una eficacia sostenida a largo plazo en la reducción de la frecuencia, duración y gravedad de las crisis en pacientes con migraña crónica...	Businesswire
01-Jul-2023	Shareholder Alert: Robbins LLP Informs Investors of Class Action Against ImmunityBio, Inc. (IBRX)	Businesswire
30-Jun-2023	Healthcare ‘bucks global trend’ hitting two year high for M&A in first half of 2023	LSEG
30-Jun-2023	Boost for transparency as highest ever rate of healthcare professionals named on Disclosure UK	ABPI
30-Jun-2023	Enterome announces first patient dosed in a Phase 1/2 trial with third OncoMimics™ immunotherapy, EO4010, in Metastatic Colorectal Cancer	Enterome
30-Jun-2023	New research shows large-scale underdiagnosis of Chronic Kidney Disease in the NHS	Primary Care Diabetes Europe (PCDE)
30-Jun-2023	New number of shares and votes in Moberg Pharma AB (publ)	Moberg Pharma
30-Jun-2023	BioSenic provides financial update	BioSenic
30-Jun-2023	ABB celebrates 85 years of the technology that revolutionized emissions monitoring	ABB
30-Jun-2023	LILLY RECEIVES MHRA MARKETING AUTHORISATION IN GREAT BRITAIN FOR MIRIKIZUMAB (OMVOH ®▼) FOR THE TREATMENT OF ELIGIBLE ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS.1	LILLY
30-Jun-2023	DelSiTech announces positive topline clinical data from phase 1 trial with its sustained release eye drop platform	DelSiTech
30-Jun-2023	Legionnaire Disease Testing Market is predicted to register a CAGR of 9% from 2022 to 2032	MARKITWIRED